ABT Molecular Imaging, Inc., in Knoxville, TN, has successfully achieved the installation and clinical use of its next-generation Biomarker Generator by the Sveta Marina University Hospital in Bulgaria. ABT’s next-generation product integrates a compact accelerator and micro-chemistry with integrated quality control, for single-dose biomarker production.
Prior to the installation of ABT’s “Dose on Demand” Biomarker Generator System, Sveta Marina University Hospital imported FDG from a neighboring country via air travel, which dramatically limited scheduling availability and increased the cost to perform the PET/CT study. “By providing our own in-house FDG production, we are able to provide more cost-effective PET/CT services to our patients. The clinical images produced using the new ABT Biomarker Generator, and our advanced PET/CT Scanner, proved to be an excellent combination for our hospital,” stated Prof. Aneliya Klisarova, Head of the Nuclear Medicine Department.
Tom Welch, President and CEO of ABT Molecular Imaging, said, “ABT is excited to see the vision of our company, increasing the use and usefulness of PET, being realized at Sveta Marina University Hospital. The management and specialists of the hospital have shown great professionalism in all project phases. We are honored to partner with such an institution in their effort to provide the best care to the patients in Bulgaria, and we expect to continue our partnership in the future by enabling access to new PET radiopharmaceuticals. We look forward to replicating our success throughout the region as well as our growing installed base throughout the world.”
Sveta Marina University Hospital is the largest diagnostic and consultative medical university complex in Varna. The hospital partnered with Molecular Solutions Bulgaria (MSB), an official representative of ABT for the region, dedicated to bridging the gap between medical innovations and the healthcare sector in developing countries. MSB’s General Manager, Tomislav Zanev, stated “We are very proud of our partnership with Sveta Marina University Hospital, and we look forward to advancing the use of molecular imaging in the region with ABT’s unique technology.”
About ABT Molecular Imaging, Inc.
ABT Molecular Imaging is a medical imaging company marketing the Biomarker Generator, which produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use. The company was founded in 2006 by industry experts in the molecular imaging industry. ABT’s investor partners include Intersouth Partners, River Cities Capital and two TNInvestco Funds, Council & Enhanced Tennessee Fund and Limestone Fund. The company is headquartered in Knoxville, Tennessee. For more information, visit www.advancedbiomarker.com